Actor and advocate Mariska Hargitay has partnered with Bristol Myers Squibb to launch "Investigating Myeloma," a disease awareness campaign honoring the 20th anniversary of her father Mickey ...

ONS study shows education improved oncology nurses' confidence discussing medical cannabis, helping reduce stigma and support ...

A survivor shares her personal journey with stage 2A breast cancer, from choosing a bilateral mastectomy to navigating ...

Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...

The SunMo trial was evaluating the novel combination of mosunetuzumab and polatuzumab — not conventional chemotherapy, but a ...

A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive ...

Genotype-informed surveillance should pair colonoscopy with upper endoscopy when MLH1/MSH2 mutations or family history ...

Maintenance pembrolizumab plus olaparib yielded an ORR of 28% versus 18% with olaparib alone, indicating incremental antitumor activity in a biomarker-defined metastatic pancreatic cancer subgroup.

Adding Opdivo (nivolumab) and Yervoy (ipilimumab) to chemotherapy did not improve how long patients with HER2-negative ...

Dr. Maurie Markman, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, ...

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...